Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual MeetingPRNewsWire • 06/04/21
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I DisorderPRNewsWire • 06/01/21
Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 05/28/21
Alkermes (ALKS) Up 3.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/28/21
Alkermes Announces the Appointment of Emily Peterson Alva to its Board of DirectorsPRNewsWire • 05/20/21
Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or CancerPRNewsWire • 05/13/21
Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness MonthPRNewsWire • 05/03/21
Alkermes Plc (ALKS) CEO Richard Pops on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/28/21
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual MeetingPRNewsWire • 04/28/21
Alkermes Launches New Disease State Website to Offer Education About Alcohol DependencePRNewsWire • 04/27/21
Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With MelanomaPRNewsWire • 04/27/21
Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial ResultsPRNewsWire • 04/21/21